Clinical trials: Bone Remodeling
Osteoporosis
A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects
The primary objective of this study is to assess the effect of AMG 162 (denosumab) treatment on the lumbar spine BMD at month 12 and safety profile across the dose range tested (14, 60 and 100 mg SC once every 6 months) in…
- Trial name
- NCT00306189
- Testing
- 100 mg AMG 162, 60 mg AMG 162, 14 mg AMG 162
- Volunteers
- 212 people
- Sponsor
- Amgen
Disorder of Bone Density and Structure, Unspecified
Effects of rhIGF-1 on Bone Metabolism in Adolescent Girls With Anorexia Nervosa
Adolescents and young adults with anorexia nervosa (AN) are at high risk for low bone mineral density at a time when healthy adolescents are rapidly accruing bone, with implications for peak bone mass and fracture risk in later…
- Trial name
- 814 (NCT00720122)
- Testing
- Recombinant human insulin like growth factor-1 (rhIGF-1)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Massachusetts General Hospital
Anorexia Nervosa
Effect Of Biomechanical Stimulation On Skeletal Health In Adolescent And Young Women With Anorexia Nervosa
This study will evaluate the effects of a novel, non-pharmacologic intervention for the prevention of deleterious changes in bone density and strength in adolescents with anorexia nervosa (AN), a disease commonly treated with…
- Trial name
- NCT01100567
- Testing
- Low-magnitude mechanical stimulation platform
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Boston Children's Hospital
Post Menopausal Osteoporosis
A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis
This study will evaluate whether an early positive response to once-monthly oral ibandronate in treatment-naive participants with postmenopausal osteoporosis is predictive of efficacy later in treatment.
- Trial name
- NCT02598934
- Testing
- Ibandronate
- Where
- 53 sites in United States, Puerto Rico
- Volunteers
- 308 people
- Sponsor
- Hoffmann-La Roche
Postmenopausal Women With Osteoporosis
Effect of Stopping Risedronate After Long Term Treatment on Bone Turnover
The effects of stopping long-term (7 years) and short term (2 years) risedronate therapy on BMD (bone mineral density) and BTMs (bone turnover markers) will be summarized.
- Trial name
- NCT01249261
- Testing
- Risedronate
- Where
- 13 sites in Australia, Belgium and 6 more
- Volunteers
- 61 people
- Sponsor
- Warner Chilcott